<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00971061</url>
  </required_header>
  <id_info>
    <org_study_id>1465087</org_study_id>
    <nct_id>NCT00971061</nct_id>
  </id_info>
  <brief_title>Ahmed Glaucoma Valve and Single-Plate Molteno Implants in Treatment of Refractory Glaucoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanak Eye Surgery Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanak Eye Surgery Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of the Ahmed valve
      implant (AVI) and the Molteno single-plate implant (MSPI) in eyes with refractory glaucoma
      during a follow-up period of 24 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra Ocular pressure (IOP)</measure>
    <time_frame>Month 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra Ocular pressure (IOP)</measure>
    <time_frame>day 1,week 1, and months 1, 3, 6, 9, 12 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in visual acuity</measure>
    <time_frame>day 1,week 1, and months 1, 3, 6, 9, 12, 18, and 24.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-glaucoma medications</measure>
    <time_frame>week 1, and months 1, 3, 6, 9, 12, 18, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean deviation of visual field,</measure>
    <time_frame>week 1, and months 1, 3, 6, 9, 12, 18, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intra- and postoperative complications</measure>
    <time_frame>week 1, and months 1, 3, 6, 9, 12, 18, and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Refractory Glaucoma</condition>
  <arm_group>
    <arm_group_label>MSPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Molteno single-plate implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ahmed valve implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ahmed valve implant</intervention_name>
    <description>184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)</description>
    <arm_group_label>AVI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Molteno single-plate implant (MSPI)</intervention_name>
    <description>134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)</description>
    <arm_group_label>MSPI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  refractory glaucoma, defined as uncontrolled IOP despite maximal anti-glaucoma
             medication, previously failed nonseton surgical treatment, or a combination thereof.

        Exclusion Criteria:

          -  age less than 40 years

          -  a visual acuity of no light perception

          -  lens opacity

          -  elevated IOP associated with silicone oil previous glaucoma drainage device
             implantation in the same eye

          -  previous cyclodestructive treatment

          -  increased risk of endophthalmitis posterior segment disorders

          -  pre-existing ocular comorbidities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nader Nassiri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor, Department of Ophthalmology, Imam Hussein Medical Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nariman Nassiri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Researcher, Vanak Eye Surgery Center, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ghazal Kamali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>4th-year Resident, Department of Ophthalmology, Imam Hussein Medical Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanak Eye Surgery Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2009</study_first_posted>
  <last_update_submitted>September 3, 2009</last_update_submitted>
  <last_update_submitted_qc>September 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2009</last_update_posted>
  <keyword>Ahmed valve</keyword>
  <keyword>single-plate Molteno implant</keyword>
  <keyword>refractory glaucoma</keyword>
  <keyword>surgical treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

